Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David J Messenheimer

Showing results (1-10 of 5) with videos related to

Pageof 1
Sort By:
Journal of Immunology (Baltimore, Md. : 1950)|March 20, 2016
Multispectral Imaging of T and B Cells in Murine Spleen and TumorZipei Feng, Shawn M Jensen, David J Messenheimer, et al.
Surgical Oncology Clinics of North America|May 14, 2019
Future Research Goals in ImmunotherapyTyler W Hulett, Bernard A Fox, David J Messenheimer, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 1, 2017
Timing of PD-1 Blockade Is Critical to Effective Combination Immunotherapy with Anti-OX40David J Messenheimer, Shawn M Jensen, Michael E Afentoulis, et al.
Plos One|June 10, 2016
Optimizing Timing of Immunotherapy Improves Control of Tumors by Hypofractionated Radiation TherapyKristina H Young, Jason R Baird, Talicia Savage, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|January 27, 2023
Povetacicept, an Enhanced Dual APRIL/BAFF Antagonist That Modulates B Lymphocytes and Pathogenic Autoantibodies for the Treatment of Lupus and Other B Cell-Related Autoimmune DiseasesLawrence S Evans, Katherine E Lewis, Daniel DeMonte, et al.
Pageof 1

Showing results (1-10 of 5) with videos related to

Sort By:
Pageof 1
Journal of Immunology (Baltimore, Md. : 1950)|March 20, 2016
Multispectral Imaging of T and B Cells in Murine Spleen and TumorZipei Feng, Shawn M Jensen, David J Messenheimer, et al.
Surgical Oncology Clinics of North America|May 14, 2019
Future Research Goals in ImmunotherapyTyler W Hulett, Bernard A Fox, David J Messenheimer, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 1, 2017
Timing of PD-1 Blockade Is Critical to Effective Combination Immunotherapy with Anti-OX40David J Messenheimer, Shawn M Jensen, Michael E Afentoulis, et al.
Plos One|June 10, 2016
Optimizing Timing of Immunotherapy Improves Control of Tumors by Hypofractionated Radiation TherapyKristina H Young, Jason R Baird, Talicia Savage, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|January 27, 2023
Povetacicept, an Enhanced Dual APRIL/BAFF Antagonist That Modulates B Lymphocytes and Pathogenic Autoantibodies for the Treatment of Lupus and Other B Cell-Related Autoimmune DiseasesLawrence S Evans, Katherine E Lewis, Daniel DeMonte, et al.
Pageof 1